Comparison of diagnostic and prognostic capabilities of 18F-FDG-PET/CT, 131I-scintigraphy, and diffusion-weighted magnetic resonance imaging for postoperative thyroid cancer

Japanese Journal of Radiology

Volumn 29, Issue 6, 2011, Pages 413-422

  Nagamachi, Shigeki ^a   Wakamatsu, Hideyuki ^a   Kiyohara, Shogo ^a   Nishii, Ryuichi ^a   Mizutani, Youichi ^a   Fujita, Seigo ^a   Futami, Shigemi ^a   Arita, Hideo ^a   Kuroki, Masaomi ^a   Nakada, Hiroshi ^a   Uchino, Noriko ^a   Tamura, Shozo ^a   Kawai, Keiichi ^b  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

131I whole body scintigraphy; 18F FDG PET CT; DTC; DWI; Prognosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; THYROID CANCER; THYROID SCINTISCANNING;

ADENOCARCINOMA, FOLLICULAR; ADENOCARCINOMA, PAPILLARY; ADULT; AGED; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 80052747890     PISSN: 18671071     EISSN: 1867108X     Source Type: Journal    
DOI: 10.1007/s11604-011-0572-z     Document Type: Article

References (50)

1. C.K. Hoh C. Schiepers M.A. Seltzer S.S. Gambhir D.H. Silverman J. Czernin, et al. 1997 PET in oncology: will it replace the other modalities? Semin Nucl Med 27 94 106 9144854 10.1016/S0001-2998(97)80042-6 1:STN:280:DyaK2s3ptVSluw%3D%3D (Pubitemid 27194757)
2. 18F-FDG PET in oncology J Nucl Med 49 480 508 18287273 10.2967/jnumed.107.047787 (Pubitemid 351355215)
3. F. Grunwald A. Schomburg H. Bender E. Klemm C. Menzel T. Bultmann, et al. 1996 Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer Eur J Nucl Med 23 312 319 8599963 10.1007/BF00837630 1:STN:280:DyaK287ntFamsg%3D%3D (Pubitemid 26089112)
4. M. Dietlein K. Scheidhauer E. Voth P. Theissen H. Schicha 1997 Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer Eur J Nucl Med 24 1342 1348 9371865 10.1007/s002590050158 1:STN:280: DyaK1c%2FktF2gsw%3D%3D (Pubitemid 27507513)
5. U. Feine R. Lietzenmayer J.P. Hanke J. Held H. Wohrle W. Muller-Schauenburg 1996 Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer J Nucl Med 37 1468 1472 8790195 1:CAS:528:DyaK28XlvF2msb0%3D (Pubitemid 26321624)
6. 99mTc-sestamibi scintigraphy in differentiated thyroid cancer Thyroid 7 327 335 9226199 10.1089/thy.1997.7.327 1:STN:280:DyaK2szmvFOmug%3D%3D (Pubitemid 27295127)
7. M. Zoller S. Kohlfuerst I. Igerc E. Kresnik H.J. Gallowitsch I. Gomez, et al. 2007 Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? Eur J Nucl Med Mol Imaging 34 487 495 17103166 10.1007/s00259-006-0276-2 (Pubitemid 46426997)
8. R.J. Robbins S.M. Larson 2008 The value of positron emission tomography (PET) in the management of patients with thyroid cancer Best Pract Res Clin Endocrinol Metab 22 1047 1059 19041831 10.1016/j.beem.2008.10.001
9. M. Dietlein K. Scheidhauer E. Voth P. Theissen H. Schicha 1998 Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm? Nuklearmedizin 37 12 17 9467164 1:STN:280: DyaK1c7ivVaitQ%3D%3D
10. T. Shiga E. Tsukamoto K. Nakada K. Morita T. Kato M. Mabuchi, et al. 2001 Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma J Nucl Med 42 414 419 11337516 1:STN:280: DC%2BD3MvjsFKnsA%3D%3D (Pubitemid 32207390)
11. L. Pace E. Nicolai M. Klain M. Salvatore 2009 Diagnostic value of FDG PET/CT imaging Q J Nucl Med Mol Imaging 53 503 512 19910903 1:STN:280: DC%2BD1MjlvFynsg%3D%3D
12. A. Razfar B.F. Branstetter A. Christopoulos S.O. Lebeau S.P. Hodak D.E. Heron, et al. 2010 Clinical usefulness of positron emission tomography-computed tomography in recurrent thyroid carcinoma Arch Otolaryngol Head Neck Surg 136 120 125 20157055 10.1001/archoto.2009.215
13. 123I-MIBG scintigraphy Ann Nucl Med 22 395 401 18600417 10.1007/s12149-008-0128-1 (Pubitemid 351938512)
14. K. Nakanishi M. Kobayashi K. Nakaguchi M. Kyakuno N. Hashimoto H. Onishi, et al. 2007 Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion-weighted images Magn Reson Med Sci 6 147 155 18037795 10.2463/mrms.6.147
15. J.C. Vilanova J. Barcelo 2008 Diffusion-weighted whole-body MR screening Eur J Radiol 67 440 447 18430538 10.1016/j.ejrad.2008.02.040
16. A. Bohlscheid D. Nuss S. Lieser H.P. Busch 2008 Tumor search with diffusion-weighted imaging: first experience Rofo 180 302 309 18370348 1:STN:280:DC%2BD1c3ht1Wksw%3D%3D (Pubitemid 351985168)
17. J.A. Choi E.Y. Kang H.K. Kim I.C. Song Y.I. Kim H.S. Kang 2008 Evolution of VX2 carcinoma in rabbit tibia: magnetic resonance imaging with pathologic correlation Clin Imaging 32 128 135 18313577 10.1016/j.clinimag.2007.08.021 (Pubitemid 351289051)
18. A. Baur O. Dietrich M. Reiser 2003 Diffusion-weighted imaging of bone marrow: current status Eur Radiol 13 1699 1708 12759770 10.1007/s00330-003-1873- 0 (Pubitemid 36869366)
19. Z. Bozgeyik S. Coskun A.F. Dagli Y. Ozkan F. Sahpaz E. Ogur 2009 Diffusion-weighted MR imaging of thyroid nodules Neuroradiology 51 193 198 19165474 10.1007/s00234-008-0494-3
20. T. Mori H. Nomori K. Ikeda K. Kawanaka S. Shiraishi K. Katahira, et al. 2008 Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography J Thorac Oncol 3 358 364 18379353 10.1097/JTO.0b013e318168d9ed (Pubitemid 351489475)
21. M.E. Toubert E. Hindie L. Rampin A. Al-Nahhas D. Rubello 2007 Distant metastases of differentiated thyroid cancer: diagnosis, treatment and outcome Nucl Med Rev Cent East Eur 10 106 109 18228215 (Pubitemid 351266293)
22. 18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning J Clin Endocrinol Metab 91 498 505 16303836 10.1210/jc.2005-1534 1:CAS:528:DC%2BD28XhsFKntb0%3D (Pubitemid 43236915)
23. G.U. Hung K.W. Lee P.Y. Liao L.H. Yang K.T. Yang 2008 The influence of I-131 therapy on FDG uptake in differentiated thyroid cancer Ann Nucl Med 22 481 485 18670854 10.1007/s12149-008-0149-9
24. S. Nagamachi S. Jinnouchi R. Nishii Y. Ishida S. Fujita S. Futami, et al. 2004 Cerebral blood flow abnormalities induced by transient hypothyroidism after thyroidectomy: analysis by Tc-99m-HMPAO and SPM96 Ann Nucl Med 18 469 477 15515745 10.1007/BF02984562 (Pubitemid 39410245)
25. C.F. Eustatia-Rutten J.W. Smit J.A. Romijn E.P. van der Kleij-Corssmit A.M. Pereira M.P. Stokkel, et al. 2004 Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis Clin Endocrinol (Oxf) 61 61 74 10.1111/j.1365-2265.2004.02060.x 1:CAS:528:DC%2BD2cXmslKitbg%3D (Pubitemid 38951647)
26. M. Schlumberger E. Baudin 1998 Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma Eur J Endocrinol 138 249 252 9539294 10.1530/eje.0.1380249 1:CAS:528:DyaK1cXis1ars78%3D (Pubitemid 28154769)
27. H. Palmedo J. Bucerius A. Joe H. Strunk N. Hortling S. Meyka, et al. 2006 Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management J Nucl Med 47 616 624 16595495 (Pubitemid 46768462)
28. L.S. Freudenberg A. Frilling H. Kuhl S.P. Muller W. Jentzen A. Bockisch, et al. 2007 Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer Eur Radiol 17 3139 3147 18004607 10.1007/s00330-007-0682-2 (Pubitemid 350147679)
29. 131I-negative thyroid cancer Ann Surg Oncol 15 286 292 17882493 10.1245/s10434-007-9611-5
30. 18F-FDG-PET and PET/CT imaging in thyroid cancer Biomed Pharmacother 60 409 413 16891093 10.1016/j.biopha.2006.07.008 1:CAS:528:DC%2BD28XhtVagtLbK (Pubitemid 44428097)
31. S. Buhmann Kirchhoff C. Becker H.R. Duerr M. Reiser A. Baur-Melnyk 2009 Detection of osseous metastases of the spine: comparison of high resolution multi-detector-CT with MRI Eur J Radiol 69 567 573 18191356 10.1016/j.ejrad. 2007.11.039
32. S.K. Grebe I.D. Hay 1996 Thyroid cancer nodal metastases: biologic significance and therapeutic considerations Surg Oncol Clin N Am 5 43 63 8789493 1:STN:280:DyaK28zotFCrsg%3D%3D (Pubitemid 26047382)
33. M.J. Schlumberger 1998 Papillary and follicular thyroid carcinoma N Engl J Med 338 297 306 9445411 10.1056/NEJM199801293380506 1:STN:280: DyaK1c%2Fpt1SktA%3D%3D (Pubitemid 28065257)
34. M. Matoba H. Tonami T. Kondou H. Yokota K. Higashi H. Toga, et al. 2007 Lung carcinoma: diffusion-weighted MR imaging: preliminary evaluation with apparent diffusion coefficient Radiology 243 570 577 17400757 10.1148/radiol.2432060131 (Pubitemid 46649714)
35. I. Hasegawa P.M. Boiselle K. Kuwabara M. Sawafuji H. Sugiura 2008 Mediastinal lymph nodes in patients with non-small cell lung cancer: preliminary experience with diffusion-weighted MR imaging J Thorac Imaging 23 157 161 18728541 10.1097/RTI.0b013e318166d2f5
36. T.A. Heusner S. Kuemmel A. Koeninger M.E. Hamami S. Hahn A. Quinsten, et al. 2010 Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging Eur J Nucl Med Mol Imaging 37 1077 1086 20204355 10.1007/s00259-010-1399-z
37. S. Satoh Y. Kitazume S. Ohdama Y. Kimula S. Taura Y. Endo 2008 Can malignant and benign pulmonary nodules be differentiated with diffusion-weighted MRI? AJR Am J Roentgenol 191 464 470 18647918 10.2214/AJR.07.3133
38. R. Rong C.Y. Zhang X.Y. Wang 2008 Normal appearance of large field diffusion weighted imaging on 3.0 T MRI Chin Med Sci J 23 158 161 18853850 10.1016/S1001-9294(09)60031-6
39. T. Horie T. Takahara T. Ogino T. Okuaki M. Honda Y. Okumura, et al. 2008 Trial of artifact reduction in body diffusion weighted imaging development and basic examination of "TRacking Only Navigator"(TRON method) Nippon Hoshasen Gijutsu Gakkai Zasshi 64 1157 1166 18840953
40. C.K. Kim B.K. Park J.J. Han T.W. Kang H.M. Lee 2007 Diffusionweighted imaging of the prostate at 3 T for differentiation of malignant and benign tissue in transition and peripheral zones: preliminary results J Comput Assist Tomogr 31 449 454 17538295 10.1097/01.rct.0000243456.00437.59 (Pubitemid 46849917)
41. C. Are J.F. Hsu R.A. Ghossein H. Schoder J.P. Shah A.R. Shaha 2007 Histological aggressiveness of fluorodeoxyglucose positronemission tomogram (FDG-PET)-detected incidental thyroid carcinomas Ann Surg Oncol 14 3210 3215 17713821 10.1245/s10434-007-9531-4 (Pubitemid 47594286)
42. M. Rivera R.A. Ghossein H. Schoder D. Gomez S.M. Larson R.M. Tuttle 2008 Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma Cancer 113 48 56 18484584 10.1002/cncr.23515 (Pubitemid 351976385)
43. 18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer J Clin Endocrinol Metab 85 1107 1113 10720047 10.1210/jc.85.3.1107 1:CAS:528:DC%2BD3cXisFOru7Y%3D (Pubitemid 32269357)
44. 18F] fluorodeoxyglucose and positron emission tomography Neurology 32 1323 1329 6983044 (Pubitemid 13218489)
45. H. Uematsu N. Sadato T. Ohtsubo T. Tsuchida S. Nakamura K. Sugimoto, et al. 1998 Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors J Nucl Med 39 453 459 9529291 1:STN:280: DyaK1c7ovVWnsg%3D%3D (Pubitemid 28136843)
46. H. Joensuu A. Ahonen 1987 Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose J Nucl Med 28 910 914 3572549 1:STN:280:DyaL2s7pslKmsg%3D%3D (Pubitemid 17096461)
47. K. Watanabe H. Nomori T. Ohtsuka T. Naruke A. Ebihara H. Orikasa, et al. 2006 [F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas Jpn J Clin Oncol 36 403 409 16782729 10.1093/jjco/hyl043 (Pubitemid 44304797)
48. 131I uptake Clin Endocrinol (Oxf) 68 108 116 10.1111/j.1365-2265. 2007.03008.x 1:CAS:528:DC%2BD1cXisVynsLs%3D (Pubitemid 350243490)
49. J.C. Ricarte-Filho M. Ryder D.A. Chitale M. Rivera A. Heguy M. Ladanyi, et al. 2009 Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1 Cancer Res 69 4885 4893 19487299 10.1158/0008-5472.CAN-09-0727 1:CAS:528:DC%2BD1MXmsFGksrg%3D
50. N. Aygun 2008 Imaging of recurrent thyroid cancer Otolaryngol Clin North Am 41 1095 1106 19040971 10.1016/j.otc.2008.05.003